Revolution Medicines reports $198 million Q3 sales for pancreatic cancer drug Rasonque, calling it best oncology launch ever
Revolution Medicines' new pancreatic cancer drug Rasonque generated $198 million in revenue in the third quarter, far exceeding analyst expectations of $50‑100 million.
The drug received FDA approval on Aug 26, and within five weeks more than 5,000 U.S. patients were treated, according to the company.
About 2,700 prescribers administered Rasonque, with roughly 40% from academic centers and the remainder from community practices.
Analysts, such as TD Cowen's Tyler Van Buren, described the early performance as the best oncology drug launch in history, though company executives warned that it is too early to draw firm conclusions.
This writeup was produced by pharmadog from original reporting by BioPharma Dive.
Original headline: “Revolution’s Rasonque off to best cancer drug launch ‘in history’”
read at BioPharma Dive ↗
comments(0)
5-min edit window · permanent after that